Gene Expression Profiling of Metastatic Colon Cancer (CCCWFU 89B03)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Colorectal Cancer
- Sponsor
- Wake Forest University Health Sciences
- Enrollment
- 10
- Primary Endpoint
- Gene expression changes that occur at each metastatic site (i.e., liver, lungs, and peritoneum)
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer may help doctors identify biomarkers related to cancer.
PURPOSE: This laboratory study is using gene expression profiling to evaluate normal tissue and tumor tissue from patients with colon cancer that has spread to the liver, lungs, or peritoneum.
Detailed Description
OBJECTIVES: * Evaluate gene expression profiles in normal and tumor tissue from patients with colon cancer metastatic to the liver, lungs, or peritoneum. * Establish cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum. * Determine the specific gene expression changes that result in the manifestation of the drug-resistant phenotype for each metastatic site. OUTLINE: This is a pilot study. Tumor and normal tissue collected during surgery are analyzed for gene expression profiling by cDNA microarray. Tissue is also analyzed for thymidylate synthase (TS) gene expression by quantitative PCR and for protein expression by western blot. Gene expression patterns are correlated with TS levels.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Gene expression changes that occur at each metastatic site (i.e., liver, lungs, and peritoneum)
Time Frame: day 1
Development of cell lines from primary colon tumors metastatic to the liver, lungs, or peritoneum
Time Frame: day 1